Evidence map›Paper›PMID 37405504›Full record

ArticleEuropean radiology2023

Development and external validation of a prediction model for the transition from mild to moderate or severe form of COVID-19.

Maéva Zysman, Julien Asselineau, Olivier Saut, Eric Frison, Mathilde Oranger, Arnaud Maurac, Jeremy Charriot, Rkia Achkir, Sophie Regueme, Emilie Klein and 12 more

Registry-linked trialOpen access · hybridAbstract read
In one paragraph

Article in European radiology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04481620 (Evelopment and Validation of a Prediction Model for the Transition From Mild to Moderate Form of COVID-19, Using Data From Chest CT), which is not on this map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
3.0field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04481620 completednot on this map

Evelopment and Validation of a Prediction Model for the Transition From Mild to Moderate Form of COVID-19, Using Data From Chest CT

TypeobservationalSponsorUniversity Hospital, BordeauxRan2020 to 2021Enrolled1,329ConditionsCOVID-19
3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. HAntimicrobial agents and chemotherapy · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors at 6 institutions in 1 country.

Maéva ZysmanCHU Bordeaux, 33600, Pessac, France. maeva.zysman@chu-bordeaux.fr.
Julien AsselineauCHU Bordeaux, 33600, Pessac, France.
Olivier Saut"Institut de Mathématiques de Bordeaux" (IMB), UMR5251, CNRS, University of Bordeaux, 351 Cours Libération, 33400, Talence, France.
Eric FrisonCHU Bordeaux, 33600, Pessac, France.
Mathilde OrangerPôle Des Spécialités Médicales/Département de Pneumologie, Université de Lorraine, Centre Hospitalier Régional Universitaire (CHRU) Nancy, Service de Radiologie Et d'Imagerie, Nancy, France.
Arnaud MauracCHU Bordeaux, 33600, Pessac, France.
Jeremy CharriotDepartment of Respiratory Diseases, Arnaud de Villeneuve Hospital, Montpellier University Hospital, CEDEX 5, 34295, Montpellier, France.
Rkia AchkirCHU Bordeaux, 33600, Pessac, France.
Sophie ReguemeCHU Bordeaux, 33600, Pessac, France.
Emilie KleinCHU Bordeaux, 33600, Pessac, France.
Sébastien BommartDepartment of Respiratory Diseases, Arnaud de Villeneuve Hospital, Montpellier University Hospital, CEDEX 5, 34295, Montpellier, France.
Arnaud BourdinDepartment of Respiratory Diseases, Arnaud de Villeneuve Hospital, Montpellier University Hospital, CEDEX 5, 34295, Montpellier, France.
Gael DournesCHU Bordeaux, 33600, Pessac, France.
Julien CasteigtPneumology Clinic, St Médard en Jalles, France.
Alain BlumPôle Des Spécialités Médicales/Département de Pneumologie, Université de Lorraine, Centre Hospitalier Régional Universitaire (CHRU) Nancy, Service de Radiologie Et d'Imagerie, Nancy, France.
Gilbert FerrettiFrance Service de Radiologie Diagnostique Et Interventionnelle, Université Grenoble Alpes, CHU Grenoble-Alpes, Grenoble, France.
Bruno DeganoFrance Service de Radiologie Diagnostique Et Interventionnelle, Université Grenoble Alpes, CHU Grenoble-Alpes, Grenoble, France.
Rodolphe ThiébautCHU Bordeaux, 33600, Pessac, France.
Francois ChabotPôle Des Spécialités Médicales/Département de Pneumologie, Université de Lorraine, Centre Hospitalier Régional Universitaire (CHRU) Nancy, Service de Radiologie Et d'Imagerie, Nancy, France.
Patrick BergerCHU Bordeaux, 33600, Pessac, France.
Francois LaurentCHU Bordeaux, 33600, Pessac, France.
Ilyes BenlalaCHU Bordeaux, 33600, Pessac, France.
Université de Bordeaux · FRCentre Hospitalier Universitaire de Bordeaux · FRInserm · FRCentre Hospitalier Universitaire de Grenoble · FRCentre Hospitalier Régional et Universitaire de Nancy · FRCentre National de la Recherche Scientifique · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesCOVID-19 pandemic seems to be under control. However, despite the vaccines, 5 to 10% of the patients with mild disease develop moderate to critical forms with potential lethal evolution. In addition to assess lung infection spread, chest CT helps to detect complications. Developing a prediction model to identify at-risk patients of worsening from mild COVID-19 combining simple clinical and biological parameters with qualitative or quantitative data using CT would be relevant to organizing optimal patient management.

methodsFour French hospitals were used for model training and internal validation. External validation was conducted in two independent hospitals. We used easy-to-obtain clinical (age, gender, smoking, symptoms' onset, cardiovascular comorbidities, diabetes, chronic respiratory diseases, immunosuppression) and biological parameters (lymphocytes, CRP) with qualitative or quantitative data (including radiomics) from the initial CT in mild COVID-19 patients.

resultsQualitative CT scan with clinical and biological parameters can predict which patients with an initial mild presentation would develop a moderate to critical form of COVID-19, with a c-index of 0.70 (95% CI 0.63; 0.77). CT scan quantification improved the performance of the prediction up to 0.73 (95% CI 0.67; 0.79) and radiomics up to 0.77 (95% CI 0.71; 0.83). Results were similar in both validation cohorts, considering CT scans with or without injection.

conclusionAdding CT scan quantification or radiomics to simple clinical and biological parameters can better predict which patients with an initial mild COVID-19 would worsen than qualitative analyses alone. This tool could help to the fair use of healthcare resources and to screen patients for potential new drugs to prevent a pejorative evolution of COVID-19. CLINICAL

trial registrationNCT04481620. CLINICAL RELEVANCE STATEMENT: CT scan quantification or radiomics analysis is superior to qualitative analysis, when used with simple clinical and biological parameters, to determine which patients with an initial mild presentation of COVID-19 would worsen to a moderate to critical form. KEY POINTS: • Qualitative CT scan analyses with simple clinical and biological parameters can predict which patients with an initial mild COVID-19 and respiratory symptoms would worsen with a c-index of 0.70. • Adding CT scan quantification improves the performance of the clinical prediction model to an AUC of 0.73. • Radiomics analyses slightly improve the performance of the model to a c-index of 0.77.

Indexed as

COVID-19HumansModels, StatisticalPandemicsPrognosisRetrospective StudiesSARS-CoV-2Artificial intelligenceClinical decision rulesCOVID-19Tomography, X-ray computed

Identifiers

PMID37405504
PMCPMC10667132
OpenAlexW4383186638

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.